EC approves  subcutaneous route of administration in Sandoz biosimilar, Binocrit

EC approves subcutaneous route of administration in Sandoz biosimilar, Binocrit

novartis_logo
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in its drug Binocrit (epoetin alfa), a prescription medicine that stimulates the bone marrow to produce red blood cells (anemia in either the nephrology or oncology setting).
“By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients” said Carol Lynch, Global Head Biopharmaceuticals, Sandoz.
The EU approval was based on data from the SENSE clinical study – an open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
The company says it is committed to increasing patient access to high-quality, life-enhancing biosimilars

About author

You might also like

May & Baker goes natural

Launches herbal products May & Baker Nig. Plc., Nigeria’s first pharmaceutical company, opened a new chapter in its operation in the country last week, with the launch of a new

PSN worries over rate of members leaving Nigeria 

The Pharmaceutical Society of Nigeria, (PSN), has expressed worry over the rate its members are leaving the country for greener pastures. Chairman of the association, Osun State chapter, Prof Moses

Nigeria gears up for VivaTech 2019

Sanofi connects African startups with new digital solutions to  healthcare Nigerian emerges as finalist   No fewer than 50 African startups will pitch their digital solutions for effective health care

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply